Skip to content

AtWork: The Relation Between Cognitive Functioning, Common Mental Disorders and Work Functioning

AtWork: The Relation Between Cognitive Functioning, Common Mental Disorders and Work Functioning

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07349550
Acronym
AtWork
Enrollment
200
Registered
2026-01-20
Start date
2024-01-01
Completion date
2032-08-01
Last updated
2026-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety, Depression - Major Depressive Disorder

Keywords

Metacognitive therapy, Work focus, Depression, Anxiety, Sick leave

Brief summary

Depression and anxiety affects levels of function across different levels like work, increasing levels of sick leave and as well as cognitive functioning. In the current study patients at risk of sick leave with depression and anxiety receive metacognitive therapy and work focus in an ordinary outpatient clinic. Impaired cognitive functioning may also be of importance in the return to work process and degree of sick leave. It is important to get a better understanding of how cognitive functioning is related to sick leave and if it predicts return to work, and if cognitive functioning is changed due to psychological treatment.

Detailed description

The study is a naturalistic study exploring cognitive functioning of patients with common mental disorders (CMD) treated with metacognitive therapy and work focused interventions, and changes over time. Sick leave is common for patients with CMD, also after having completed treatment for CMD. Why patients remain on sick leave after having completed treatment is underexplored. Potential reasons may be that work and sick leave is not addressed during therapy, there could be issues related to the work place, also there may be characteristics related to the patients functioning that is underexplored. In the latter context, little knowledge regarding the relations between cognitive functioning, symptoms of CMD and work functioning. Previous studies have investigated neuropsychological functions in relation to work related stress and stress-related exhaustion, and found worse performance on cognitive tasks compared to healthy controls. Although stress-related exhaustion can be considered a phenomenon related to CMD, there are no studies the investigators are aware of that investigate neuropsychological predictors specifically related to CMD and work functioning. A review from 2022 specifically aimed to identify neuropsychological predictors of vocational rehabilitation outcomes in individuals with MDD specifically, and found no studies. This clearly demonstrates a knowledge gap that this project would fill. E.g., lower cognitive functioning after successful treatment of CMD is related to increased risk of additional sick leave. With this in mind, increasing our knowledge of these variables can help clinicians identify patients at risk for additional sick leave, even after successful treatment. A previous study at the same clinic has identified three subgroups in a sample of patients with CMD at risk of sick leave. The first group was never on sick leave. The second group returned to work after sick leave during or shortly after treatment. In the third group half of the patients remained on sick leave or disability. To better understand characteristics of such subgroups it is relevant to explore standard clinical information given in the patient's journal. This project is mainly, but not exclusively a PhD-project. The time schedule for the project will go beyond the time for the PhD, especially long-time follow-up. The main aims of the project are the following: To explore how descriptive variables, CMD symptoms, and cognitive functioning are associated with work functioning (sick leave or risk for sick leave) before treatment. And what is the interplay between symptoms, cognitive profiles and sick leave. To explore whether cognitive functioning can predict outcomes of both symptoms of CMD and degree of sick leave, and if cognitive functioning changes through MCT and work focused interventions.

Interventions

None listed

Sponsors

Norwegian University of Science and Technology
Lead SponsorOTHER
Diakonhjemmet Hospital
CollaboratorOTHER
The Research Council of Norway
CollaboratorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* diagnosis of depression and/or anxiety, * at risk of sick leave

Exclusion criteria

* personality disorders cluster A or B, * ongoing substance abuse, * symptoms of psychosis, * acute suicidality, * serious somatic disorders

Design outcomes

Primary

MeasureTime frameDescription
Patient Health Questionnaire-9 (PHQ-9)Measured at pre-treatment and at therapy completion, an average of 10 weekly sessions, and at 6, 12 months follow-upMeasure of depressive symptoms (PHQ-9) range 0-27 higher scores indicate higher degree of depressive symptoms
Generalized Anxiety Disorder (GAD-7)Measured at pre-treatment and at therapy completion, an average of 10 weekly sessions, and at 6, 12 months follow-upAnxiety symptoms (GAD-7) range 0-21 higher scores indicating higher degree of anxiety symptoms
Changes in sick leaveMeasured at pre-treatment and at therapy completion, an average of 10 weekly sessions, and at 6, 12 months follow-upSick leave is collected from national register data measured in number of days of sick leave.

Countries

Norway

Contacts

CONTACTOdin Hjemdal, PhD
odin.hjemdal@ntnu.no+4773597889

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026